Bispecific Antibody definition
Examples of Bispecific Antibody in a sentence
David Gruber1, Mikhail Kozlov2, Romas Skudas3, 1MedImmune Ltd, Cambridge, Cambridgeshire, UK; 2EMD Millipore, Bedford, MA, USA; 3EMD Millipore, Darmstadt, Hessen, GERMANY 4:20 PM Purification of a Common Light Chain Bispecific Antibody using Contichrom (MCSGP).
The Bispecific Antibody Product enjoys the advantages of high affinity, strong inhibitory activity, high preparation concentration, good stability and low dosing frequency.
VEGF/ANG2 Tetravalent Bispecific Antibody Product is a class I innovative biological product with a unique nanobody design for treatment of ocular fundus neovascular diseases, targeting VEGF (vascular endothelial growth factor) and ANG2 (angiopoietin 2), which effectively inhibits abnormal neovascularization and is in the preclinical stage.
In order to determine whether or not a specific Antibody or a specific Bispecific Antibody is available for inclusion in a particular Exclusive Antibody License, Medarex and Genmab shall follow the procedure set forth in this Section 16.2.2A.
Notwithstanding the above Genmab shall still be entitled to develop and commercialize such Antibody under the applicable license granted herein as a component of a Bispecific Antibody, provided Genmab notifies Medarex of this, [***], prior to the expiration of the time period in Section 7.3, in which case Section 7.3(d) shall apply.
Multiple Doses of an Anti-FGFR1/ KLB Bispecific Antibody (BFKB8488A) are Associated with a Decrease in Hepatic Fat in Patients with NAFLD.
In the event Medarex indicates to Genmab that a given Antibody or a given Bispecific Antibody is available, then such Antibody or such Bispecific Antibody will automatically be deemed to be irrevocably included in such Exclusive Antibody License.
In the event Medarex indicates to Genmab that a given Antibody or a given Bispecific Antibody is unavailable, [***].
The Bispecific Antibody Product will enrich the Group’s innovative pipeline in the ocular fundus diseases treatment field, enhancing the competitiveness of the ophthalmology business.
For each Joint Program, either Party may recommend to the other Party, at any time, Out-Licensing Commercialization rights (and optionally, Development rights) relating to the applicable Joint Bispecific Antibody and Joint Product in the Field, either in the Territory or in select countries, to a Third Party; provided, that the Lead Party shall have the [*] right to decide whether to pursue such an Out-Licensing approach.